Literature DB >> 15547749

Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms.

Jiangyong Miao1, Takeshi Kusafuka, Masahiro Fukuzawa.   

Abstract

BRAF (v-raf murine sarcoma viral oncogene homolog B1) activating mutations in a high proportion of melanomas and in a small fraction of other cancers have been recently reported. All the presented mutations of BRAF are located in exons 11 and 15, and the hotspot mutation at codon 599 accounts for 87% of BRAF mutations. Because the mutational status is unclear in pediatric solid neoplasms, we screened BRAF mutations comprehensively in our tumor series presented in childhood. Two pairs of primers were designed to amplify exons 11 and exon 15, respectively, and 181 tumor samples (65 neuroblastomas, 23 Wilms tumors, 19 hepatoblastomas, 16 teratomas, 17 rhabdomyosarcomas, 13 ganglioneuromas, etc.) were investigated by PCR-SSCP method. On agarose gel electrophoresis, amplified PCR fragments showed no size-altered changes in exons 11 and 15, and SSCP analysis revealed uniform band patterns in both exons. Subsequent direct sequencing of selected 10 samples confirmed only normal sequences without any nucleotide substitutions. The current study represents the first genetic analysis of the BRAF gene in pediatric solid tumors. Our data suggest that mutations of BRAF gene as a mechanism of tumorigenesis is unlikely to be associated with most childhood neoplasms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547749

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

2.  BRAF mutations in metanephric adenoma of the kidney.

Authors:  Toni K Choueiri; John Cheville; Emanuele Palescandolo; André P Fay; Philip W Kantoff; Michael B Atkins; Jesse K McKenney; Victoria Brown; Megan E Lampron; Ming Zhou; Michelle S Hirsch; Sabina Signoretti
Journal:  Eur Urol       Date:  2012-06-09       Impact factor: 20.096

3.  Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.

Authors:  Stephen T Keir; John M Maris; Richard Lock; E Anders Kolb; Richard Gorlick; Hernan Carol; Christopher L Morton; C Patrick Reynolds; Min H Kang; Amy Watkins; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

4.  Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program.

Authors:  E Anders Kolb; Richard Gorlick; Peter J Houghton; Christopher L Morton; Geoffrey Neale; Stephen T Keir; Hernan Carol; Richard Lock; Doris Phelps; Min H Kang; C Patrick Reynolds; John M Maris; Catherine Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

5.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

6.  Effects of RAS on the genesis of embryonal rhabdomyosarcoma.

Authors:  David M Langenau; Matthew D Keefe; Narie Y Storer; Jeffrey R Guyon; Jeffery L Kutok; Xiuning Le; Wolfram Goessling; Donna S Neuberg; Louis M Kunkel; Leonard I Zon
Journal:  Genes Dev       Date:  2007-05-17       Impact factor: 11.361

7.  Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma.

Authors:  Aaron M Udager; Jincheng Pan; Martin J Magers; Ganesh S Palapattu; Todd M Morgan; Jeffrey S Montgomery; Alon Z Weizer; Khaled S Hafez; David C Miller; James S Wolf; Jonathan B McHugh; Arul M Chinnaiyan; Saravana M Dhanasekaran; Rohit Mehra
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

8.  Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation.

Authors:  Anna Caliò; John N Eble; Ondrej Hes; Guido Martignoni; Saul E Harari; Sean R Williamson; Matteo Brunelli; Adeboye O Osunkoya; Lisha Wang; Eva Comperat; Antonio Lopez-Beltran; Mingsheng Wang; Shaobo Zhang; Kendra L Curless; Kristin M Post; Hsim-Yee Chang; Claudio Luchini; Lee Ann Baldrige; Gregory T MacLennan; Rodolfo Montironi; David J Grignon; Liang Cheng
Journal:  Oncotarget       Date:  2016-08-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.